Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.
The authors describe a new method for the production of personalised medicines utilising ultra-precise microdrop printing technology.
To restrict the use of intentionally added microplastics, the European Chemicals Agency has proposed a restriction dossier that describes various measures aimed at minimizing the use of microplastics in various industrial segments, including pharmaceuticals. In this paper, the authors discuss these restrictions.
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
An integrated CMC provider can help smaller companies to streamline development timelines and reduce project management complexity when compared with multi-provider models.
The complexity of the RNA production process creates challenges.
The IPEC-Americas event focuses exclusively on excipients and brings buyers and suppliers together.
Data integrity is crucial in unlocking novel data-based insights.
This paper provides an in-depth overview of the anatomical structure and functional dynamics of renal filtration, secretion, and reabsorption processes that govern drug clearance.
Europe needs a more standardised and consistent approach for supplying excipient information to the regulators.
The drug manufacturing ecosystem Pharma 4.0, a term coined in 2017 by the International Society for Pharmaceutical Engineers, promises a revolution across drug discovery, manufacturing, and supply chain logistics, ensuring drugs are delivered precisely when needed, and improving overall patient care.
3D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
This article looks at the relationship between a CDMO quality organization and the client.
Biopharmaceutical production faces the challenge of ensuring the quality of raw materials due to a lack of specific guidelines. By implementing effective risk assessment strategies and working with reliable, selected solution providers, biopharmaceutical manufacturers can minimize these challenges and improve product quality.
Key information is needed for excipients and their potential impact on continuous manufacturing processes.
This study suggests that using a simple centrifugal method can produce a natural polymer-blend molecule that can successfully be used as an oral delivery mechanism for poorly soluble drugs.
Technological advances hold promise for mitigating human error in the pharmaceutical industry, especially in quality assurance/quality control, by reducing the incidence of, and risk associated with, mistakes.
The latest manufacturing technologies are essential for helping pharmaceutical formulators meet up-and-coming trends in OSD treatments.
Webinar Date/Time: Tuesday, June 27th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Wednesday, June 28th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Thursday, June 29th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT
An annual survey on inspections and audits has revealed opportunities to use more flexible approaches to optimize processes.
It is vital to consider optimal cleaning and disinfection practices when operating a cleanroom.
Analytical Method Development for Synthetic Peptide Purity and Impurities Content by UHPLC - Illustrated Case Study
The authors review the current regulatory framework for the selection of drug substance starting materials.
Element offers comprehensive solutions for the entire product lifecycle.